Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.68 |
| ▸ | FAAH | O00519 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044836 | 0.93 | MAPT (0.69) | MGLLFAAHALDH1A1MAPTLMNA | |
| SCHEMBL315785 | 0.87 | MGLL (0.69) | MGLLFAAHALDH1A1MAPTLMNA | |
| SCHEMBL315992 | 0.87 | ALDH1A1 (0.69) | MGLLALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL27851988 | 0.84 | MAPT (0.61) | MGLLFAAHALDH1A1MAPTLMNA | |
| SCHEMBL8844981 | 0.82 | ALOX15 (0.72) | MGLLFAAHALDH1A1MAPTLMNA | |
| SCHEMBL26042174 | 0.82 | CYP1A2 (0.69) | MGLLFAAHALDH1A1MEN1KMT2A | |
| SCHEMBL18424173 | 0.82 | CYP1A2 (0.73) | MGLLFAAHALDH1A1MEN1KMT2A | |
| SCHEMBL12794615 | 0.81 | MGLL (0.87) | MGLLFAAHALDH1A1MAPTLMNA | |
| SCHEMBL1734128 | 0.81 | MGLL (0.63) | MGLLFAAHALDH1A1 | |
| SCHEMBL3996605 | 0.81 | MGLL (0.63) | MGLLFAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102026975-A | Piperazines as anti-obesity agents | BIOVITRUM AB PUBL | 2011-04-20 | — | — | CN | disclosed |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110046135-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (PUBL) (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046135-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (PUBL) (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046135-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (PUBL) (SE) | 2011-02-24 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| EP-2229362-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | AstraZeneca AB (SE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| WO-2009071658-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071658-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181967-A1 | New compounds I | GPR119, GLP1R, FABP4 | MGLL 169/4885FAAH 1838/4885ALDH1A1 2089/4885 |
| US-20110046135-A1 | NEW COMPOUNDS I | GPR119, GLP1R, FABP4 | MGLL 169/4885FAAH 1838/4885ALDH1A1 2089/4885 |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | GPR119, FABP4, ADIPOR2 | MGLL 143/4885FAAH 1885/4885ALDH1A1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.